Status
Not yet recruiting
Phase
Not applicable
Enrollment
40
Locations
1
Results
Not posted
Publications
0
Study summary
This study is to investigate the physiological mechanism of oxytocin system stimulation using 3,4-methylenedioxymethamphetamine (MDMA) as a physiological tool (acute oxytocin releases), not as a medication. This study seeks to test whether the oxytocin response after MDMA administration is different between individuals with autism spectrum disorder and matched healthy controls.
Oxytocin is a hypothalamic neuropeptide released both peripherally and centrally that modulates social behavior, emotional processing, and cognition through receptors in regions such as the amygdala, nucleus accumbens, and prefrontal cortex. Clinical, neurobiological, and genetic studies indicate altered oxytocin signaling in autism spectrum disorder (ASD): meta-analyses show lower peripheral oxytocin levels, reduced receptor binding in some brain areas (especially in females), and correlations between higher peripheral oxytocin receptor expression and better social functioning. Over the past two decades, oxytocin has been evaluated as a therapy for ASD, mainly to target social deficits. While exogenous oxytocin can transiently enhance social cognition and connectivity, long-term trials remain inconclusive. As with other hormone deficiencies, single basal oxytocin measurements are unreliable. An emerging alternative is the use of MDMA, which robustly increases circulating oxytocin concentrations in healthy individuals. Measuring oxytocin release after a standardized MDMA challenge could clarify whether ASD patients retain a functional oxytocinergic response, with a blunted release indicating pathway dysfunction. The OxySPECTRUM study will address this by administering a single dose of MDMA to high- functioning ASD patients and matched neurotypical controls, comparing plasma neurophysin I (equimolar oxytocin surrogate marker) area under curve (AUC) responses.
Interventions
DIAGNOSTIC_TEST
MDMA will be prepared as gelatine capsules containing 25 mg of pharmaceutically pure MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) and mannitol filler. MDMA will be administered in a single dose of 100 mg (4 capsules of 25 mg MDMA)
DIAGNOSTIC_TEST
Placebos will be prepared as identical gelatine capsules containing only mannitol filler.
Timeline
First posted
Apr 29, 2026
Study start
Jun 2026
Primary completion
Jun 2028
Study completion
Jun 2028
Results posted
Not reported
Registry updated
Apr 29, 2026
Outcomes
Change in area under the concentration time curve in plasma neurophysin I
Time frame · From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Change in area under the concentration time curve in plasma neurophysin I after a single dose administration of MDMA (100mg) as compared to placebo in the same individuals and compared between ASD patients and healthy controls.
Peak change in plasma oxytocin/neurophysin-I level
Time frame · From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Time course of plasma oxytocin/neurophysin-I levels
Time frame · From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Time course of plasma MDMA concentration
Time frame · From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Time course of pituitary hormone
Time frame · From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
Change in subjective emotional effects assessed on Subjective effects questionnaire Numeric Analog Scales (NAS)
Time frame · Throughout the treatment visit (timepoint 0, 30, 60, 90, 120, 150, 180, 240, and 300 minutes)
Subjective emotional effects will be assessed repeatedly using the subjective/emotional effects questionnaire assessed with NAS. NAS will be presented as a range from 0 to 10 marked with "not at all" on the left and "extremely" on the right.
EmBody/EmFace Task
Time frame · The test is performed once during each treatment visit and 2-2.5 hours after MDMA administration.
During the expected peak concentration of MDMA, participants will perform the EmBody/EmFace Task. Each of 42 stimuli showing body or facial expressions of angry, happy, or neutral affect (14 clips per emotion, half in front view and half in half-profile side view from the left). Stimuli last 1.5 seconds at 24 frames per second and are geometrically and optically standardized. Item order is pseudorandom to prevent sequence effects and was determined using the following constraints: the same emotion is shown no more than twice in a row; the same view per emotion is not shown consecutively (i.e., no angry-front, angry-front).
Facial emotion recognition task (FERT)
Time frame · The test is performed once during each treatment visit and 2-2.5 hours after MDMA administration.
The FERT is used to assess recognition of basic emotions. The task includes 10 neutral faces and 160 faces that express one of four basic emotions (i.e., happiness, sadness, anger, and fear), with pictures morphed between 0% (neutral) and 100% in 10% steps. Two female and two male pictures are used for each of the four emotions. The outcome measure is accuracy (proportion correct).
Reading the Mind in the Eyes Test (RMET)
Time frame · The test is administered once during each treatment visit and 2-2.5 hours after MDMA administration.
The RMET is used to assess theory of mind and emotion recognition from subtle facial cues. The task consists of 36 photographs showing only the eye region of male and female faces. For each photograph, four mental state descriptors (e.g., "anxious," "thoughtful," "playful," "serious") are presented, and participants are asked to choose the word that best matches what the person is feeling or thinking. Stimuli are displayed in random order without time restriction. The primary outcome measure is accuracy (proportion correct), with higher scores reflecting better social-cognitive performance.
Anxiety level with the State-Trait Anxiety Inventory (STAI)
Time frame · The test requires about 5 minutes.
Based on responses to 20 items, with scores ranging from 1 ("almost never") to 4 ("almost always"), a total score is calculated. The total trait score (STAI-T) ranges from 20 to 80, with higher scores indicating more pronounced anxiety and scores.
Alexithymia level using the Toronto-Alexithymia-Scale 20 (TAS-20)
Time frame · At the screening visit (about 2 minutes)
The TAS 20 has a three-factor structure: difficulty identifying feelings, difficulty describing feelings and externally oriented thinking. It includes 20 questions with scores ranging from 1 (strongly disagree) to 5 (strongly agree).
Eligibility
Inclusion Criteria for patients: * Adult patients with a confirmed diagnosis of autism spectrum disorder level 1 according to Diagnostic and Statistical Manual (DSM) V Inclusion criteria for healthy controls: * Adult healthy controls * Matched for age, sex, BMI, and oestrogen replacement/menopause/hormonal contraceptives to patients * No medication, except hormonal contraception * A score of \<32 in the Autism Spectrum Quotient Exclusion Criteria: * Participation in a trial with investigational drugs within 30 days * Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months * Consumption of alcoholic beverages \>15 drinks/week * Tobacco smoking \>10 cigarettes/day * Cardiovascular disease (coronary artery disease, heart failure, left ventricular ejection fraction (LVEF) \<40%, stroke in the last 3 months, atrial fibrillation/flutter, Wolff-Parkinson-White (WPW)-Syndrome) * Uncontrolled arterial hypertension (\>140/90 mmHg) or hypotension (\<85mmHg) * Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder) * Psychotic disorder in first-degree relatives * Pregnancy and breastfeeding * Diagnosed CKD \> grade III (GFR \< 30ml/min) * Diagnosed liver cirrhosis or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range * Confirmed epilepsy diagnosis * Diagnosed autism spectrum disorder level 2 or 3 (according to DSM V criteria)
Study locations
Switzerland. Showing up to 24 locations stored in the fast local snapshot.
University Hospital Basel, Endocrinology, Diabetes and Metabolism
Basel, Switzerland
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Wake Forest University Health Sciences · Total Hip Arthroplasty
Phase 2
Enrolling by invitation
80
2026-07
Yale University · Pain · Pituitary Surgery
Phase 2
Not yet recruiting
75
2026-07
Medical University of South Carolina · PTSD · Alcohol Use Disorder
Phase 2
Completed
175
2026-07
University Hospital, Tours · Cervical Ripening · Unfavorable Cervix
Phase 3
Recruiting
1,494
2026-07
Icahn School of Medicine at Mount Sinai · Pregnancy · Labor
Phase 3
Recruiting
281
2026-07
Elizabeth Austen Lawson · Vasopressin Deficiency
Phase 1
Recruiting
40
2026-07
Massachusetts General Hospital · Arginine Vasopressin Deficiency · Oxytocin Deficiency
Early Phase 1
Recruiting
20
2026-07
Aalto University · Induction of Birth · Cervical Ripening
Not applicable
Recruiting
40
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.